Lpath's kidney cancer drug fails mid-stage trial

(Reuters) - Drug developer Lpath Inc said its experimental drug to treat renal cell carcinoma, the most common form of kidney cancer, failed to meet its main goal in a mid-stage trial.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news